Repository navigation
Write the tesamorelin page - #84
Merged
Merged
Conversation
Second of the seven. It was noindex and is now indexable, at 93/100 on the heuristic with 100% of measured demand landing on a rendered answer. This is the best opportunity on the site by a distance: 42,127 clickstream searches at KD 3, the lowest difficulty against the highest volume of any record here, and the SERP explains why the number is believable. The result at rank 2 is a vendor product page carrying eight words of body text. The page at rank 8 has no H2 element at all. Of the three competitors scored, one has a reviewer that is a team rather than a person, and two carry no citation of any kind. The page is built on one sentence that none of them has. The pivotal trial re-randomised at 26 weeks specifically to see what happens when the drug is withdrawn, and reported in its conclusion that the visceral-fat reduction does not last beyond the duration of treatment. That reframes every other figure: a 52-week result is not a 52-week benefit if week 53 undoes it. The second thing the page does is refuse a connection the SERP makes freely. Every human study in this ledger enrolled people with HIV and antiretroviral-associated abdominal fat accumulation, which is the indication the drug was approved for. Most of the measured demand is about muscle, ageing and general fat loss, and no trial here gave tesamorelin to a healthy adult. An approval is evidence for the population and outcome it covers and not for a different one, so the page states the approval and the absence side by side. The muscle result is handled the same way. It is cited everywhere as evidence that tesamorelin builds muscle; it is a secondary exploratory analysis restricted to responders whose visceral fat had already fallen by at least 8%, and its own authors ask for it to be studied further. Triage carries no accept items, because stages 1 and 2 ran before the writing rather than after it. The Egrifta label ranks 7th for the head term and could not be retrieved: this sandbox reaches Europe PMC but not accessdata.fda.gov. The approval facts come from ChEMBL and the trials, and the audit records that. Co-Authored-By: Claude Opus 5 (1M context) <noreply@anthropic.com>
|
The latest updates on your projects. Learn more about Vercel for GitHub.
|
This branch was successfully deployed
This file contains hidden or bidirectional Unicode text that may be interpreted or compiled differently than what appears below. To review, open the file in an editor that reveals hidden Unicode characters.
Learn more about bidirectional Unicode characters
Sign up for free
to join this conversation on GitHub.
Already have an account?
Sign in to comment
1 participant
Add this suggestion to a batch that can be applied as a single commit.This suggestion is invalid because no changes were made to the code.Suggestions cannot be applied while the pull request is closed.Suggestions cannot be applied while viewing a subset of changes.Only one suggestion per line can be applied in a batch.Add this suggestion to a batch that can be applied as a single commit.Applying suggestions on deleted lines is not supported.You must change the existing code in this line in order to create a valid suggestion.Outdated suggestions cannot be applied.This suggestion has been applied or marked resolved.Suggestions cannot be applied from pending reviews.Suggestions cannot be applied on multi-line comments.Suggestions cannot be applied while the pull request is queued to merge.Suggestion cannot be applied right now. Please check back later.
Second of the seven. Was
noindex, now indexable. 93/100 heuristic, 100% of measured demand on a rendered answer.The best opportunity on the site
Highest volume against lowest difficulty of any record here. The SERP explains why that difficulty score is believable rather than an artefact:
The result at rank 2 is a vendor product page carrying eight words of body text. The page at rank 8 has no
<h2>element at all.The sentence none of them has
The pivotal trial re-randomised at 26 weeks specifically to see what happens when the drug is withdrawn, and reported in its own conclusion:
That reframes every other figure on the page. A 52-week result is not a 52-week benefit if week 53 undoes it.
A connection the page refuses to make
Every human study in this ledger enrolled people with HIV and antiretroviral-associated abdominal fat accumulation, which is the indication the drug was approved for in 2010. Most of the measured demand is about muscle, ageing and general fat loss, and no trial here gave tesamorelin to a healthy adult.
An approval is evidence for the population and outcome it covers, not for a different one. The page states the approval and the absence side by side rather than letting one imply the other.
The muscle result gets the same treatment. It is cited widely as evidence that tesamorelin builds muscle; it is a secondary exploratory analysis restricted to responders whose visceral fat had already fallen by 8% or more, and its own authors ask for it to be studied further.
Triage
No
acceptitems. The page was written against the audit's criteria rather than corrected into them, which is what running stages 1 and 2 before the writing is for.Honest limit
The Egrifta label ranks 7th for the head term and could not be retrieved: this sandbox reaches Europe PMC but not
accessdata.fda.gov,dailymed.nlm.nih.govorclinicaltrials.gov. Approval facts come from ChEMBL and the trials. Neither pivotal trial abstract declares an NCT number, so no registration table is possible for this compound from Europe PMC alone.Gates
Content validation, registry check, 36 drafter tests, loop gate at 47/47, all five link rules.
🤖 Generated with Claude Code